التفاصيل البيبلوغرافية
العنوان: |
Cancer Therapy-Induced Encephalitis |
المؤلفون: |
Nicolas P. Desbaillets, Andreas F. Hottinger |
المصدر: |
Cancers ; Volume 16 ; Issue 21 ; Pages: 3571 |
بيانات النشر: |
Multidisciplinary Digital Publishing Institute |
سنة النشر: |
2024 |
المجموعة: |
MDPI Open Access Publishing |
مصطلحات موضوعية: |
cancer, adverse event, neurotoxicity, encephalitis, autoimmune, immunotherapy, checkpoint inhibitor, CAR-T, ICANS, BiTE |
الوصف: |
Encephalitis associated with cancer therapies is a rare but serious complication that can significantly impact patients’ quality of life and it requires prompt identification and management. Over the past two decades, immunotherapy—particularly immune checkpoint inhibitors—has become a cornerstone of cancer treatment, with up to half of metastatic cancer patients in economically developed countries now receiving these therapies. The widespread adoption of immunotherapy has led to improved survival rates and long-term remissions, even in patients with advanced metastatic disease. However, as immune modulators, these therapies can trigger a range of immune-related adverse events, including a variety of novel neurological toxicities. Among these, encephalitis is of particular concern due to its potential severity, which can compromise treatment outcomes. This review aims to provide a comprehensive overview of the literature on this condition, highlighting optimal diagnostic strategies and management approaches to mitigate the risk of significant morbidity, while also comparing encephalitis induced by immunotherapy with that caused by traditional chemotherapies and targeted oncologic treatments. |
نوع الوثيقة: |
text |
وصف الملف: |
application/pdf |
اللغة: |
English |
Relation: |
Cancer Immunology and Immunotherapy; https://dx.doi.org/10.3390/cancers16213571 |
DOI: |
10.3390/cancers16213571 |
الاتاحة: |
https://doi.org/10.3390/cancers16213571 |
Rights: |
https://creativecommons.org/licenses/by/4.0/ |
رقم الانضمام: |
edsbas.9CAFC909 |
قاعدة البيانات: |
BASE |